Race Oncology (RAC) 2022年年度报告「ASX」.pdf

1、2022 Annual Report Novel RNA-directed therapeutics to treat cancer&protect the heartASX:RACCorporate Directory DIRECTORSJohn Cullity Non-Executive Chairman Phillip Lynch Managing Director and Chief Executive Officer Daniel Tillett Executive Director and Chief Scientific Officer Mary Harney Non-Execu

2、tive Director COMPANY SECRETARYPeter Webse REGISTERED OFFICELevel 36,Gateway,1 Macquarie Place Sydney NSW 2000Ph:+61 2 8051 3043 Website:AUDITORHall Chadwick WA 283 Rokeby Road Subiaco WA 6008SECURITIES EXCHANGE LISTING Race Oncology Limiteds shares are listed on the AustralianSecurities Exchange(AS

3、X Code RAC)SHARE REGISTRYAutomic Registry Services Level 5,126 Phillip Street Sydney NSW 2000Ph:1300 288 664Race Oncology Limited ACN 149 318 749 Annual Report 20221ContentsChairmans Letter 22022 Key Highlights 4Directors Report 6Auditors Independence Declaration 23Consolidated Statement of Profit o

4、r Loss and Other Comprehensive Income 24Consolidated Statement ofFinancial Position 25Consolidated Statement ofChanges in Equity 26Consolidated Statement ofCashFlows 27Notes to the Financial Statements 28Directors Declaration 50Independent Auditors Report 51ASX Additional Information 56In November 2

5、021 we shared news of our pre-clinical in vitro results that showed Zantrene could both improve the anti-cancer effect and protect the heart muscle from chemotherapeutic induced damage when used with a commonly prescribed chemotherapeutic drug,doxorubicin.This significant result was further supporte

6、d in an animal mouse model of chemotherapy-induced heart damage,with results reported in June 2022 demonstrating the ability of Zantrene to prevent heart damage and improve cancer treatment.This exciting and much-needed cardioprotection opportunity is now being assessed for clinical translation.Comm